Q-omics provides the consensus-scored DRGX profile across patient tissues and cancer cell-line models. DRGX expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, DRGX is differentially expressed in 9, with the highest sampling consensus in STAD. Additionally, DRGX RNA expression shows 9,716 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight THCA, STAD, and PCPG as cancer lineages where DRGX shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DRGX — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DRGX survival associations across molecular data types. DRGX RNA expression shows survival associations in the most cancer types (20), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DRGX RNA expression–survival associations across cancer types. High DRGX expression shows unfavorable associations in THCA, KIRC, OV, LUSC and ESCA, but favorable associations in SKCM. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify THCA as the clearest survival context for DRGX RNA expression.
This table summarizes DRGX tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for DRGX. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DRGX shows lower tumor expression in COAD and READ and higher tumor expression in STAD, LUAD, LIHC and ESCA. The STAD box plot shows higher DRGX RNA expression in tumor versus normal tissue (log2 FC = +0.852, t-test p < 0.001).
This table shows molecular features associated with DRGX in patient tissues and cancer cell lines. In patient samples, DRGX shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, DRGX RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SOFT_TISSUE.
